Fig. 9From: A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinomaDrug sensitivity analysis of the two subtypes. A Estimated IC50 of the indicated molecular targeted drugs in CPCS1 and CPCS2. B Estimated IC50 of the potential drugs in CPCS1 and CPCS2Back to article page